146 related articles for article (PubMed ID: 37414921)
21. Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication.
Philippe M; Guitton J; Goutelle S; Thoma Y; Favier B; Chtiba N; Michallet M; Belhabri A
Ther Drug Monit; 2024 Feb; 46(1):127-131. PubMed ID: 37941111
[TBL] [Abstract][Full Text] [Related]
22. FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.
Asai-Nishishita A; Kawahara M; Tatsumi G; Iwasa M; Fujishiro A; Nishimura R; Minamiguchi H; Kito K; Murata M; Andoh A
Sci Rep; 2023 Sep; 13(1):14454. PubMed ID: 37660196
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
Liu S; Cui Q; Li M; Li Z; Chen S; Wu D; Tang X
Ann Hematol; 2024 Apr; 103(4):1397-1402. PubMed ID: 38367057
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2.
Xu X; Ma W; Qiu G; Xuan L; He C; Zhang T; Wang J; Liu Q
Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887047
[TBL] [Abstract][Full Text] [Related]
25. Differential Gene Regulatory Network Analysis between Azacitidine-Sensitive and -Resistant Cell Lines.
Park H; Miyano S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542276
[TBL] [Abstract][Full Text] [Related]
26. Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
Lin Q; Ye P; Wang T; Lu Y
Ann Hematol; 2024 Jan; 103(1):335-337. PubMed ID: 37728735
[No Abstract] [Full Text] [Related]
27. The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia.
Sharma R; Zhang C; Narendran A
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895265
[TBL] [Abstract][Full Text] [Related]
28. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapy Development in Acute Myeloid Leukemia.
Totiger TM; Ghoshal A; Zabroski J; Sondhi A; Bucha S; Jahn J; Feng Y; Taylor J
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831175
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML.
Mohanty V; Baran N; Huang Y; Ramage CL; Cooper LM; He S; Iqbal R; Daher M; ; Tyner JW; Mills GB; Konopleva M; Chen K
bioRxiv; 2024 Jan; ():. PubMed ID: 38352538
[TBL] [Abstract][Full Text] [Related]
31. Hemophagocytic Lymphohistiocytosis Secondary to Refractory Acute Myeloid Leukemia Resolved after Second-Line Treatment with Azacitidine plus Venetoclax.
Zorzetto F; Scalas A; Longu F; Isoni MA; Angelucci E; Fozza C
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024011. PubMed ID: 38223479
[No Abstract] [Full Text] [Related]
32. Venetoclax and Azacitidine in the Treatment of
Ma J; Morimoto K; Pulsipher MA; Parekh C
JCO Precis Oncol; 2023 Jun; 7():e2200693. PubMed ID: 37315262
[No Abstract] [Full Text] [Related]
33. Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
Ann Hematol; 2023 Aug; 102(8):2299. PubMed ID: 37341779
[No Abstract] [Full Text] [Related]
34. Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia.
Oyogoa E; Traer E; Tyner J; Lachowiez C
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509251
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J; Urrutia S; Loghavi S; Short NJ; Issa GC; Maiti A; Abbas HA; Daver NG; Pemmaraju N; Pierce S; Chien KS; Sasaki K; Kadia TM; Hammond DE; Borthakur G; Patel K; Ravandi F; Kantarjian HM; Garcia-Manero G; DiNardo CD
Blood; 2023 Nov; 142(19):1647-1657. PubMed ID: 37441846
[TBL] [Abstract][Full Text] [Related]
36. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
37. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract][Full Text] [Related]
38. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Morales ML; García-Vicente R; Rodríguez-García A; Reyes-Palomares A; Vincelle-Nieto Á; Álvarez N; Ortiz-Ruiz A; Garrido-García V; Giménez A; Carreño-Tarragona G; Sánchez R; Ayala R; Martínez-López J; Linares M
Leukemia; 2023 Aug; 37(8):1649-1659. PubMed ID: 37422594
[TBL] [Abstract][Full Text] [Related]
39. TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.
Testa U; Castelli G; Pelosi E
Mediterr J Hematol Infect Dis; 2023; 15(1):e2023038. PubMed ID: 37435040
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Shahswar R; Beutel G; Gabdoulline R; Schwarzer A; Kloos A; Koenecke C; Stadler M; Gohring G; Behrens YL; Li Z; Dallmann LK; Klement P; Albert C; Wichmann M; Alwie Y; Benner A; Saadati M; Ganser A; Thol F; Heuser M
Haematologica; 2024 Jan; 109(1):72-83. PubMed ID: 37470150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
